Come meet Panna Sharma, CEO of AI firm Lantern Pharma (NASDAQ: LTRN). His presentation is titled "How AI Has Lit A Revolution in Longevity, Healthcare & Medicine."  It is sure to be interesting and thought provoking and will prove to be great insight for all. 

Panna Sharma is the President, CEO, and Board Member of Lantern Pharma Inc.(NASDAQ: LTRN), an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Lantern's proprietary AI and machine learning (ML) platform, RADR®, leverages over 60 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, they have accelerated the development of their growing pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody-drug conjugate (ADC) program. On average, their newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $1.0 - 2.5 million per program. Their lead development programs include a Phase 2 clinical program and multiple Phase 1 clinical trials. They have also established a wholly-owned subsidiary, Starlight Therapeutics, to focus exclusively on the clinical execution of their promising therapies for CNS and brain cancers, many of which have no effective treatment options. Their AI-driven pipeline of innovative product candidates is estimated to have a combined annual market potential of over $15 billion USD and have the potential to provide life-changing therapies to hundreds of thousands of cancer patients across the world.
‍

Learn more about how Lantern is transforming the lives of cancer patients by leveraging Artificial Intelligence and Machine Learning in order to stratify patients into responders and non-responders and more deeply understand how to personalize and develop targeted cancer therapies. This, in turn, significantly reduces the timeline and cost of treatment.

Come meet Panna Sharma, CEO of AI firm Lantern Pharma (NASDAQ: LTRN). His presentation is titled "How AI Has Lit A Revolution in Longevity, Healthcare & Medicine."  It is sure to be interesting and thought provoking and will prove to be great insight for all. 

Panna Sharma is the President, CEO, and Board Member of Lantern Pharma Inc.(NASDAQ: LTRN), an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Lantern's proprietary AI and machine learning (ML) platform, RADR®, leverages over 60 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, they have accelerated the development of their growing pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody-drug conjugate (ADC) program. On average, their newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $1.0 - 2.5 million per program. Their lead development programs include a Phase 2 clinical program and multiple Phase 1 clinical trials. They have also established a wholly-owned subsidiary, Starlight Therapeutics, to focus exclusively on the clinical execution of their promising therapies for CNS and brain cancers, many of which have no effective treatment options. Their AI-driven pipeline of innovative product candidates is estimated to have a combined annual market potential of over $15 billion USD and have the potential to provide life-changing therapies to hundreds of thousands of cancer patients across the world.
‍

Learn more about how Lantern is transforming the lives of cancer patients by leveraging Artificial Intelligence and Machine Learning in order to stratify patients into responders and non-responders and more deeply understand how to personalize and develop targeted cancer therapies. This, in turn, significantly reduces the timeline and cost of treatment.

At this event, you will be introduced to Jeffrey Meckler  who currently serves as the Chief Executive Officer to Indaptus Therapeutics (NASDAQ: INDP), bringing more than 30 years of financial and healthcare leadership experience. Most recently, Jeff was the CEO of Intec Pharma, and prior to that, CEO of Cocrystal Pharma, transforming it from a research company into a clinical and development company. Earlier in his career, Jeff was managing director of the Andra Group, a life sciences consulting firm, and acted as a director and interim CEO of Cypress Bioscience after its acquisition by Royalty Pharma. Jeff started his career at Pfizer, where he held a series of positions in manufacturing systems, market research, business development, strategic planning and corporate finance, which included playing a significant role in acquisitions and divestitures. He has also served as a director of QLT, Inc., Cocrystal Pharma, ClearFarma USA, Kyalin Bioscience, and Alveolus, and currently serves as director of Travere Therapeutics, where he also previously served as Chairman. Jeff is the past President and continues to serve on the Board of Children of Bellevue, a non-profit organization focused on advocating and developing pediatric programs at Bellevue Hospital Center. He holds a B.S. in industrial management, an M.S. in industrial administration from the Tepper School of Business at Carnegie Mellon University, and a J.D. from Fordham University’s School of Law.  

Learn more about how Indaptus Therapeutics that is building upon the long-standing observation of tumor regression in the setting of bacterial infection. They have developed a unique and patented approach designed to exploit bacteria’s natural ability to fully engage the human immune system and cure disease. Their novel insights have enabled them to create proprietary, attenuated and killed non-pathogenic gram-negative bacteria that have demonstrated broad anti-tumor and anti-viral activity in pre-clinical models to date.

This event will be co-hosted by James (Jeb) Besser the CEO of Modular Medical, Inc. (NASDAQ: MODD), a development-stage medical device company that intends to launch the next generation of insulin delivery technology. Using its patented technologies, the company seeks to eliminate the tradeoff between complexity and efficacy, thereby making top quality insulin delivery both affordable and simple to learn. Their mission is to improve access to the highest standard of glycemic control for people with diabetes taking it beyond "superusers" and providing "diabetes care for the rest of us." Modular Medical was founded by Paul DiPerna, a seasoned medical device professional and microfluidics engineer. Prior to founding Modular Medical, Mr. DiPerna was the founder (in 2005) of Tandem Diabetes and invented and designed its t:slim insulin pump. More information is available at https://modular-medical.com.

This event will be co-hosted by James (Jeb) Besser the CEO of Modular Medical, Inc. (NASDAQ: MODD), a development-stage medical device company that intends to launch the next generation of insulin delivery technology. Using its patented technologies, the company seeks to eliminate the tradeoff between complexity and efficacy, thereby making top quality insulin delivery both affordable and simple to learn. Their mission is to improve access to the highest standard of glycemic control for people with diabetes taking it beyond "superusers" and providing "diabetes care for the rest of us." Modular Medical was founded by Paul DiPerna, a seasoned medical device professional and microfluidics engineer. Prior to founding Modular Medical, Mr. DiPerna was the founder (in 2005) of Tandem Diabetes and invented and designed its t:slim insulin pump. More information is available at https://modular-medical.com.

Come meet Eric A. Adams, CEO of InMed Pharmaceuticals (NASDAQ: INM), a global leader in the research, development and manufacturing of rare cannabinoids, including clinical and preclinical programs targeting the treatment of diseases with high unmet medical needs. Specifically, InMed is developing a pipeline of rare cannabinoids across a spectrum of therapeutic applications with large unmet medical needs. Their pharmaceutical programs include a Phase 2 clinical trial, which has recently completed enrollment, studying the safety and efficacy of cannabinol (CBN) cream for epidermolysis bullosa and preclinical programs in glaucoma and neurodegenerative disease. In addition, InMed together with it’s subsidiary BayMedica, also has significant know-how in developing proprietary manufacturing approaches to produce cannabinoids for various market sectors.

Eric Adams is a seasoned pharmaceutical executive with over 30 years of experience in capital formation, global market development, mergers & acquisitions, licensing and corporate governance. Prior to becoming CEO of InMed, Mr. Adams previously served as CEO at enGene Inc in Vancouver and held senior positions in global market development with QLT Inc, Abbott Labratories and Fresenius AG in Germany.

Learn more about InMed’s responsibility to the safety and health of their people, the communities they call home, and the environment they operate in.

Come meet Daniel Teper, PharmD, MBA, the Co-Founder, Chairman & Chief Executive Officer, of Cytovia Therapeutics, a company that aims to accelerate patient access to transformational cell therapies and immunotherapies, addressing several of the most challenging unmet medical needs in cancer. Cytovia focuses on harnessing the innate immune system by developing complementary and disruptive iPSC-derived Natural Killer (iNK) cell and Flex-NK™ bispecific antibody platforms. The company is developing three types of iNK cells: unedited iNK cells, TALEN® gene-edited iNK cells with improved function and persistence, and TALEN® gene-edited iNK cells with chimeric antigen receptors (CAR-iNKs) to improve tumor-specific targeting. The second complementary cornerstone technology is a quadrivalent multifunctional antibody platform designed to engage natural killer cells by targeting NKp46 using Cytovia's proprietary Flex-NK™ technology.

These two technology platforms are being used to develop treatment for patients with solid tumors such as HCC and glioblastoma as well as hematological malignancies such as refractory multiple myeloma. Headquartered in Aventura, FL., Cytovia has research and development laboratories in Natick, MA. The company's own R&D work is augmented through scientific partnerships with Cellectis, CytoImmune, the Hebrew University of Jerusalem, INSERM, the New York Stem Cell Foundation, the National Cancer Institute, and the University of California San Francisco (UCSF).

Cytovia has developed a partnership with CytoLynx Therapeutics focused on research and development, manufacturing, and commercialization activities in Greater China and beyond.

Find out more at www.cytoviatx.com 

Learn More

We are excited to be hosting a Tribe Public Webinar Presentation and Q&A Event with Eric Dobmeier, President & Chief Executive Officer of Chinook Therapeutics (NASDAQ: KDNY) on Thursday, April 15th, 2021 (8:30 am pacific / 11.30 am eastern). His presentation is titled "Revolutionizing The Treatment of Kidney Disease."

Mr. Dobmeier previously was the President and CEO of Silverback Therapeutics, a Seattle-based biotechnology company in the immuno-oncology space. Prior to that, he spent more than 15 years at Seattle Genetics, most recently as Chief Operating Officer, where he oversaw business development, corporate communications, manufacturing, program/alliance management activities and corporate strategy initiatives. While at Seattle Genetics, Eric was also directly involved in raising more than $1.2 billion in equity capital, and led negotiation and completion of multiple corporate alliances with leading biotechnology and pharmaceutical companies. Earlier in his career, he represented technology companies in connection with public and private financings, mergers and acquisitions and corporate partnering transactions. Eric has a J.D. from University of California, Berkeley School of Law and an undergraduate degree from Princeton University. He is also a director of Atara Biotherapeutics and Adaptive Biotechnologies.

Chinook is a clinical-stage biopharmaceutical company discovering, developing and commercializing precision medicines for rare, severe chronic kidney diseases, a severe and growing worldwide problem with a lack of effective treatments often leading to dialysis, transplantation, and high costs to health care systems. In the U.S. alone, kidney diseases affect an estimated 37 million people and account for over $120 billion in annual costs.

We will have limited seats for this event as we have a nice group confirmed already, so please reply quickly.

Back to Events

We are excited to be hosting Tribe Public's Next Webinar Presentation and Q&A Event which will be held Wednesday, April 13 (8:30 am PT/ 11:30 am ET). Our events are approximately 30 minutes in duration.

Mr. Steve Shum, Chief Executive Officer in CEO of INVO Bioscience (NASDAQ: INVO) will deliver a presentation titled "Democratizing Infertility - A Severely Underserved Global Market." He will be also be available for a 5-10 minute Q&A session at the end of the presentation. Send Questions to email: research@tribepublic.com.

INVO Bioscience (NASDAQ: INVO) is a medical device company focused on creating simplified, lower cost treatments for patients diagnosed with infertility. Their solution, the INVO® Procedure, is a disruptive new technology. The INVO Procedure is a revolutionary in vivo method of vaginal incubation that offers patients a more natural and intimate experience.

Their lead product, the INVOcell®, is a patented medical device used in infertility treatment and is considered an Assisted Reproductive Technology (ART). The INVOcell is the first Intravaginal Culture (IVC) system in the world used for the natural in vivo incubation of eggs and sperm during fertilization and early embryo development, as an alternative to traditional In Vitro Fertilization (IVF) and Intrauterine Insemination (IUI).

Their mission is to increase access to care and expand fertility treatment across the globe with a goal to lower the cost of care and increase availability of care.

Back to Events

We are excited to be hosting a Tribe Public Webinar Presentation and Q&A Event with Eric Dobmeier, President & Chief Executive Officer of Chinook Therapeutics (NASDAQ: KDNY) on Tuesday, January 26th, 2021 (8:30 am pacific / 11.30 am eastern). His presentation is titled "ALIGNED in the Fight Against Kidney Diseases"

Mr. Dobmeier previously was the President and CEO of Silverback Therapeutics, a Seattle-based biotechnology company in the immuno-oncology space. Prior to that, he spent more than 15 years at Seattle Genetics, most recently as Chief Operating Officer, where he oversaw business development, corporate communications, manufacturing, program/alliance management activities and corporate strategy initiatives. While at Seattle Genetics, Eric was also directly involved in raising more than $1.2 billion in equity capital, and led negotiation and completion of multiple corporate alliances with leading biotechnology and pharmaceutical companies. Earlier in his career, he represented technology companies in connection with public and private financings, mergers and acquisitions and corporate partnering transactions. Eric has a J.D. from University of California, Berkeley School of Law and an undergraduate degree from Princeton University. He is also a director of Atara Biotherapeutics and Adaptive Biotechnologies.

Chinook is a clinical-stage biopharmaceutical company discovering, developing and commercializing precision medicines for rare, severe chronic kidney diseases, a severe and growing worldwide problem with a lack of effective treatments often leading to dialysis, transplantation, and high costs to health care systems. In the U.S. alone, kidney diseases affect an estimated 37 million people and account for over $120 billion in annual costs.

We will have limited seats for this event as we have a nice group confirmed already, so please reply quickly.

Back to Events